A new study found less than .1% of transgender and gender-diverse teens are prescribed puberty blockers or gender-affirming ...

A nonprofit is trying to get the FDA to approve crucial methods of gender-affirming care. Its battle will be even more ...

Fewer than 1 in 1,000 U.S. adolescents with commercial insurance received gender-affirming medications during a recent ...

A recent study also found that not a single transgender or gender-diverse child younger than 12, in a group of about 5 million youth studied, received hormones.

The use of gender-affirming medical care for trans teens was rare between 2018 to 2022, according to a new study published in ...

Among the restrictions are preventing minors from beginning to receive puberty blockers and hormone therapy for treatment of ...

Further, he told Fortune, “We don't have any peer reviewed estimates of the rate of accessing hormones or puberty blockers among youth, and so it was really important for us to get a handle on ...

Puberty blockers and gender-affirming hormones are rarely prescribed to U.S. transgender and gender diverse (TGD) adolescents, according to a new study from researchers at Harvard T.H. Chan School of ...

“It echoes past work that has found that gender-affirming medical care, including puberty blockers and hormone treatment, is ...

The study therefore concludes that, from 2018 through 2022, “receipt of puberty blockers and hormones was rare.” And it’s not just health “experts” who apply a double standard in how they characterize ...

Sponsor Message The care at issue includes puberty blockers and cross-sex hormone therapy — medications that help transgender teens develop characteristics that align with their gender identity.